Novavax, CPL complete Indian vax facility

A facility for the manufacture of vaccines using Novavax's virus-like particle technology is currently undergoing validation outside Ahmadabad, India. The plant has the capacity to produce 60 million doses per year.

CPL Biologicals, a joint venture Cadila Pharmaceuticals and Novavax, announced completion of construction. The JV plans to produce seasonal and pandemic flu vaccines.

Cadila says the VLP recombinant technology will permit fast vaccine-production response for pandemics. But CPL is still lacking Indian regulatory approval to conduct clinical trials in-country for VLP-based swine flu vaccine. Meanwhile, Indian drugmakers have recently come online as producers of egg-based flu vaccines.

- here's the article

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)